INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 452m ago
HOUSE PTR51m ago
SEC 13F51m ago
ROBINHOOD CHAIN51m ago
Corporate insider
PR

Preblick Ryan

Chief Financial OfficerCIK 0002014866

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 1
Max Insider Score30
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
23
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1.36M
36.0K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Indivior Pharmaceuticals, Inc.Chief Financial Officer · Feb 12, 2026
9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M
—
6,302 sh
Mar 14, 2026
Mar 17, 2026
traded Mar 14, 2026
+3d
SEC FORM 4

Evidence

12
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$88K
2,843 sh
Mar 14, 2026Mar 17, 2026
traded Mar 14, 2026
+3dSEC FORM 4

Evidence

9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
6,302 sh
Mar 14, 2026Mar 17, 2026
traded Mar 14, 2026
+3dSEC FORM 4

Evidence

30
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Tax withholding
F$2.80M
87.6K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

17
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
86.9K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

9
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Option exercise
M—
113.5K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

13
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
37.4K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

15
PR
Preblick RyanChief Financial Officer
INDVIndivior Pharmaceuticals, Inc.
Grant or award
A—
113.5K sh
Feb 9, 2026Feb 12, 2026
traded Feb 9, 2026
+3dSEC FORM 4

Evidence